American Cancer Society

Healthcare Management Administrators Names Aadam Hussain as Chief Executive Officer and President

Retrieved on: 
Wednesday, January 17, 2024
Change Healthcare, HMA, OHSU, Culture, Partnership, University, Growth, Strategic planning, Cambia Health Solutions, Creativity, SVP, American Cancer Society, Management

BELLEVUE, Wash., Jan. 17, 2024 /PRNewswire/ -- Healthcare Management Administrators is pleased to welcome Aadam Hussain as its next president and chief executive officer to lead the company into its next phase of growth.

Key Points: 
  • BELLEVUE, Wash., Jan. 17, 2024 /PRNewswire/ -- Healthcare Management Administrators is pleased to welcome Aadam Hussain as its next president and chief executive officer to lead the company into its next phase of growth.
  • Hussain brings extensive healthcare experience to the role with a career spanning nearly two decades that focused on M&A integration, strategic planning, investing, and scaling businesses.
  • Prior to Cambia, he held numerous executive level roles with Change Healthcare, a healthcare technology company, and Health Evolution Partners, a healthcare focused private equity firm.
  • Hussain will succeed Lindsay Harris, who has been appointed chief commercial officer at Cambia Health Solutions, and who served as HMA's leader since 2020.

FIVE-YEAR SURVIVAL RATE FOR PANCREATIC CANCER INCREASED TO 13% SIGNALING MORE PROGRESS AND MORE HOPE FOR PATIENTS

Retrieved on: 
Wednesday, January 17, 2024
Death, Obesity, Pancreatic cancer, Woman, LOS, Pancreatic Cancer Action Network, Patient, JD, Risk, Research, Incidence, Clinical trial, Survival, Disease, Metastasis, MBA, Pancreas, Doctor of Philosophy, Knowledge, News, American Cancer Society, Medical imaging

LOS ANGELES, Jan. 17, 2024 /PRNewswire/ -- The five-year survival rate for pancreatic cancer has increased to 13%, up for the third year in a row according to the American Cancer Society's Cancer Facts & Figures 2024 released today. A decade ago, the five-year survival rate was only 6% so the increase signals important progress with more patients living longer. The trend in survival rates is primarily driven by patients diagnosed with localized disease and better management of patients diagnosed at earlier stages.

Key Points: 
  • A decade ago, the five-year survival rate was only 6% so the increase signals important progress with more patients living longer.
  • The trend in survival rates is primarily driven by patients diagnosed with localized disease and better management of patients diagnosed at earlier stages.
  • "However, not enough progress is being made for patients diagnosed with metastatic disease and we need to continue to find better treatment options for those patients."
  • "PanCAN's research priorities are to find an early detection strategy and accelerate treatments for (pancreatic cancer) patients.

Cancer Mortality Still Declining, but Progress Threatened by Increasing Incidence as Projected New Cancer Cases Top Two Million for 2024

Retrieved on: 
Wednesday, January 17, 2024
Mortality, Death, Obesity, Woman, Family, Patient, Research, Incidence, Prostate cancer, ACS, Public policy, Smoking, Health equity, Breast cancer, Cancer, Government, Vaccination, Lung cancer, Life expectancy, Thyroid cancer, Liver, HPV, Stomach, Cervical cancer, Editorial, American Cancer Society, Annual report, Breast, Colorectal cancer, Prostate, Prevalence

ATLANTA, Jan. 17, 2024 /PRNewswire/ -- The American Cancer Society (ACS) today released Cancer Statistics, 2024, the organization's annual report on cancer facts and trends. The new data show overall cancer mortality has continued to decline, resulting in over 4 million fewer deaths in the United States since 1991. However, this progress is jeopardized by increasing incidence for 6 of the top 10 cancers as the projected number of new diagnoses now tops 2 million (2,001,140) for the first time. These important findings are published today in CA: A Cancer Journal for Clinicians, alongside its consumer-friendly companion, Cancer Facts & Figures 2024, available on cancer.org.

Key Points: 
  • ATLANTA, Jan. 17, 2024 /PRNewswire/ -- The American Cancer Society (ACS) today released Cancer Statistics, 2024, the organization's annual report on cancer facts and trends.
  • The new data show overall cancer mortality has continued to decline, resulting in over 4 million fewer deaths in the United States since 1991.
  • These important findings are published today in CA: A Cancer Journal for Clinicians , alongside its consumer-friendly companion, Cancer Facts & Figures 2024, available on cancer.org.
  • Mortality rates continue to increase by 2% per year for uterine corpus (endometrial) cancer, one of the few cancers with increasing mortality.

Focal Medical Receives FDA Clearance to Initiate Phase 1b Clinical Trial of ACT-IOP-003, a Targeted Therapeutic Product in Development for Pancreatic Cancer

Retrieved on: 
Tuesday, January 9, 2024
Research, Professional Services, Pharmaceutical, Oncology, Venture Capital, Medical Devices, Surgery, Clinical Trials, Science, Biotechnology, FDA, Health, Other Science, ACT, Hope, Pancreatic cancer, Investigational New Drug, Neoplasm, Patient, Incidence, University of North Carolina, Professor, Multimedia, Food and Drug Administration, Survival, University, IND, Food, Safety, Disease, Medicine, LANR, Toxicity, American Cancer Society, Clinical trial, Pancreas, Pharmaceutical industry

Focal Medical, Inc., (“Focal”) a privately held biopharmaceutical company developing a targeted therapeutic system to treat inoperable tumors and to deliver genomic medicines, today announced U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application to initiate a Phase 1b clinical trial of ACT-IOP-003, the Company’s first targeted therapeutic product.

Key Points: 
  • Focal Medical, Inc., (“Focal”) a privately held biopharmaceutical company developing a targeted therapeutic system to treat inoperable tumors and to deliver genomic medicines, today announced U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application to initiate a Phase 1b clinical trial of ACT-IOP-003, the Company’s first targeted therapeutic product.
  • The trial will evaluate the safety and tolerability of targeted delivery of gemcitabine to locally advanced nonresectable (LANR) pancreatic tumors.
  • According to The American Cancer Society, the incidence of pancreatic cancer in the U.S. is more than 62,000 cases annually and it represents the third leading cause of cancer death.
  • The multi-center, open label, modified dose escalation phase 1b clinical trial will assess the safety, tolerability, and clinical activity of the implantable ACT-IOP-003 targeted therapeutic product delivering gemcitabine directly into the pancreas to treat LANR pancreatic cancer.

Shorla Oncology Announces FDA Filing Acceptance of New Drug Application for Novel Formulation to Treat Breast and Ovarian Cancer

Retrieved on: 
Tuesday, January 9, 2024
Oncology, Health, FDA, Consumer, Women, Pharmaceutical, Biotechnology, American Cancer Society, Woman, Patient, Agency, Breast cancer, NDA, New Drug Application, Breast, Pharmaceutical industry

Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the US Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for a novel formulation to treat breast and ovarian cancer.

Key Points: 
  • Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the US Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for a novel formulation to treat breast and ovarian cancer.
  • The Agency assigned a Prescription Drug User Fee Act (“PDUFA”) action date of June 29th, 2024.
  • “This is an important step in improving access to and administration of a drug that will help women suffering from breast and ovarian cancer,” said Sharon Cunningham, Chief Executive Officer and Co-Founder of Shorla Oncology.
  • “It also marks a significant milestone regarding Shorla’s efforts to bring innovative oncology products to market.”
    More than 350,000 women will be diagnosed with breast cancer in the U.S in 2023, according to the American Cancer Society.1

New Survey by The Harris Poll Highlights Gaps in Cervical Cancer Screening Access

Retrieved on: 
Wednesday, January 10, 2024
Ageing, Woman, World Health Organization, Patient, Privacy, Health, Health equity, Knowledge, Embarrassment, Cancer, BDX, Risk, Cervical cancer, Food, Papanikolaou, The Harris Poll, HPV, Infection, American Cancer Society, Birth control

FRANKLIN LAKES, N.J., Jan. 10, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the results of a Harris Poll survey of women in the U.S., U.K. and Sweden, which shines a spotlight on the differences in access to cervical cancer screening and prevention.

Key Points: 
  • Self-collection for cervical cancer screening is a viable option for increasing access and health equity.
  • (In the U.S., the American Cancer Society recommends HPV primary screening for cervical cancer every five years for women aged 25-65.)
  • The results showed that most women consider cervical cancer screening a critical part of their health management (86% Sweden, 81% U.K., 76% U.S.).
  • More knowledge about high-risk HPV types and cervical cancer screening can empower people with a cervix to take greater control of their own health."

Canadian Cancer Society's 9th annual Dry Feb raises funds to support people affected by cancer

Retrieved on: 
Tuesday, January 9, 2024
Hope, Family, Wheel, Research, Drinking, Beer, CCS, Friends, Cancer, Risk, American Cancer Society, Multiple myeloma, Wine, B cell, Canadian Cancer Society, Tourism

TORONTO, Jan. 9, 2024 /CNW/ - The Canadian Cancer Society (CCS) is challenging people in Canada to "go dry" this February for its 9th annual Dry Feb campaign.

Key Points: 
  • TORONTO, Jan. 9, 2024 /CNW/ - The Canadian Cancer Society (CCS) is challenging people in Canada to "go dry" this February for its 9th annual Dry Feb campaign.
  • "Changing attitudes and perceptions around our relationships with alcohol are a new frontier in cancer prevention and healthy living," said Andrea Seale, CEO of the Canadian Cancer Society.
  • In fact, in 2023, over two thirds of Dry Feb participants cited the health benefits of eliminating alcohol as their reason for participating in Dry Feb again.
  • Every day and every dollar will make a meaningful difference in the lives of all those affected by cancer.

Teal Health Partners with Leading Health Organizations in a Nationwide Clinical Trial for their Self-Collect Device for Cervical Cancer Screening, the Teal Wand™

Retrieved on: 
Tuesday, January 9, 2024
Cervical cancer, Woman, Privacy, Research, Associate, Collection, Mount Sinai Morningside, SAN, University of Colorado, University of Wisconsin–Madison, University, Johns Hopkins, Yale University, Teal, Disease, Hospital, Health literacy, FDA, Doctor of Philosophy, Head, OBGYN, HPV, Clinical trial, Education, Trial of the century, American Cancer Society, Birth control

SAN FRANCISCO, Jan. 9, 2024 /PRNewswire/ -- Today, in honor of Cervical Cancer Awareness Month, Teal Health, a women's health company focused on increasing access to cervical cancer screenings in the US, announces the SELF-CERV clinical study, in progress at leading health organizations including Johns Hopkins, Yale University, University of Colorado, University of Wisconsin, Washington University, and many more. Teal Health's clinical trial is designed to support FDA submission and approval of their novel at-home self-collect device, the Teal Wand™. By offering an alternative to an in-person doctor's visit for a speculum exam, Teal Health will be able to provide women and people with a cervix a choice and greater access to this critical health screening, on which 1 in 4 women in the US are not up-to-date.

Key Points: 
  • Teal Health's clinical trial is designed to support FDA submission and approval of their novel at-home self-collect device, the Teal Wand™.
  • More than 50% of these diagnoses are later stage and among people who did not have a recent screening.
  • HPV testing is recommended as the preferred cervical cancer screening method by multiple medical guidelines, including the American Cancer Society.
  • This Cervical Cancer Awareness Month, Teal Health is raising awareness about the importance of life-saving cervical cancer screening with their 'Close the Screening Gap' initiative.

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Retrieved on: 
Monday, January 8, 2024
Phase, Marketing, Quality of life, Food, Survival, Internet, IND, Radiation, Shuttle, FDA, Disease, Brain, Orphan, Society, Glioblastoma, RT, Letter, American Cancer Society, Cancer, Patient, MGMT, Pharmaceutical industry

Receipt of the letter allows Shuttle to commence the Phase II study.

Key Points: 
  • Receipt of the letter allows Shuttle to commence the Phase II study.
  • Shuttle Pharma is currently finalizing site enrollment with 'first patient, first dose' expected in the coming months.
  • "We are excited to have been granted approval to commence Ropidoxuridine's Phase II clinical trial following the receipt of the FDA's 'Safe to Proceed' letter," stated Shuttle Pharma's Chairman and CEO, Anatoly Dritschilo, M.D.
  • Shuttle Pharma has received Orphan Drug Designation from the FDA, providing potential marketing exclusivity upon first FDA approval for the disease.

Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million

Retrieved on: 
Monday, January 8, 2024
Medical Devices, Women, Seniors, Men, Health Technology, Biotechnology, General Health, Consumer, Health, Oncology, Liver, Database, MDNA, Medicine, Multimedia, Stomach, Woman, Ovarian cancer, Acquisition, Lung, Breast, WHO, Colorectal cancer, Prevalence, Mitochondrion, Prostate cancer, World Health Organization, Cancer, Liquid biopsy, Knowledge, Endometriosis, American Cancer Society, Prostate-specific antigen, Biomarker, Diagnosis, Global health, Overdiagnosis, Security (finance), PSA, Medical imaging

This strategic move reinforces Pearsanta’s dedication to enhancing patient outcomes through early disease detection and the power of precision diagnostics.

Key Points: 
  • This strategic move reinforces Pearsanta’s dedication to enhancing patient outcomes through early disease detection and the power of precision diagnostics.
  • The platform includes a rich biomarker portfolio addressing a wide range of high-priority health concerns beyond oncology, extending into areas of substantial medical need.
  • Highlights from the asset portfolio include:
    The Mitomic Endometriosis Test (MET™) is in development as a blood-based assay for diagnosis of endometriosis.
  • The overarching goal is to enhance clinical outcomes by offering non-invasive or minimally invasive testing at the early stages of disease progression.